DIMERIX ANNOUNCES POSITIVE TOP-LINE RESULTS IN
PHASE 2a CLINICAL STUDY OF DMX-200 IN FSGS
Highlights
• Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients
• DMX-200 was found to be generally safe and well-tolerated in FSGS patients
• 86% of patients demonstrated a reduction of proteinuria with DMX-200 versus placebo
• A 29% reduction in proteinuria was observed across all patients receiving DMX-200 compared to
placebo
• 29% of patients achieved a >40% reduction in proteinuria on DMX-200 compared to placebo
• Multiple patients from both FSGS and diabetic kidney disease studies continue on DMX-200 via
TGA Special Access Scheme
• Statistically powered Phase 2 study in diabetic kidney disease results due in 4 - 6 weeks
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study, page-4
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.015(4.48%) |
Mkt cap ! $175.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 31.5¢ | $1.333M | 4.143M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 727594 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 170412 | 4 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
32.0¢ |
Change
-0.015 ( 3.15 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 33.5¢ | 31.5¢ | 2261030 | ||
| Last updated 15.51pm 26/04/2024 ? | |||||
| DXB (ASX) Chart |